用于敲除STT3A基因的sgRNA、siRNA及其应用
By designing sgRNA and siRNA sequences targeting STT3A and silencing the STT3A gene using a lentiviral vector, the lack of targeted therapy for renal cell carcinoma in existing technologies has been addressed, achieving significant inhibition of renal cell carcinoma proliferation and increased sensitivity to ferroptosis inducers.
CN122405620APending Publication Date: 2026-07-17THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL
- Filing Date
- 2026-03-16
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
There is currently no effective method for treating renal cell carcinoma by targeting the STT3A gene. STT3A is highly expressed in renal cell carcinoma but has not been verified as a therapeutic target.
Method used
We designed and constructed sgRNA and siRNA sequences targeting STT3A, silenced the STT3A gene using a lentiviral vector, and increased the sensitivity of tumor cells to ferroptosis inducers by inhibiting STT3A expression, thus preparing a drug for treating renal cancer.
Benefits of technology
Significantly silencing STT3A expression enhanced the sensitivity of renal cell carcinoma cells to ferroptosis inducers, demonstrating that STT3A is a potential therapeutic target for renal cell carcinoma and has the potential to develop targeted therapy strategies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122405620A_ABST
Abstract
本发明公开一种用于敲除STT3A基因的sgRNA、siRNA及其应用，涉及生物医药技术领域。一种用于敲除STT3A基因的sgRNA，所述sgRNA的靶位点序列如SEQ ID No.1或SEQ ID No.2所示。本发明证实了抑制STT3A基因表达可抑制人肾透明细胞癌细胞对肿瘤细胞铁死亡的敏感性，证明STT3A是一种潜在的治疗肾癌的新型靶点，有利于进一步研究由STT3A异常激活所引起的肿瘤相关疾病发生发展机制。鉴于STT3A作为一种潜在的肾癌治疗靶点，因此本发明的提供的STT3A的靶向沉默序列及其相关生物试剂，可用于研究和制备治疗肾癌的药物。
Need to check novelty before this filing date? Find Prior Art